Kalexo Bio
kalexobio.com
Actively hiring
Cardiometabolic Therapeutics
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Kalexo Bio is focused on reducing risk and improving the lives of people with cardiovascular disease, through bold innovation in siRNA-based therapeutics.
News
Mabwell and Aditum launch Kalexo Bio for siRNA therapy development
Aditum Bio will fund Kalexo Bio, and both companies will collaborate to advance 2MW7141 into clinical trials.
Read more
Report
迈威生物与Aditum Bio联合创立Kalexo Bio 推进心血管新药研发- DoNews快讯
迈威生物与Aditum Bio共同宣布成立合资企业Kalexo Bio并达成全球独家授权协议共同开发双靶点siRNA创新药物2MW7141该药物专注于心血管疾病治疗领域标志着双 ...
Read more
Report
迈威生物与Aditum Bio合作成立 Kalexo Bio共同推进心血管领域siRNA创新药的开发 - 进展专区 - 生物谷
迈威生物与 Aditum Bio Fund 3, L.P.宣布成立 Kalexo Bio, Inc.并就心血管领域双靶点 siRNA 创新药 2MW7141 达成全球独家授权协议
Read more
Report
Kalexo Bio launches to develop Mabwell's 2MW7141
Mabwell (Shanghai) Bioscience Co. Ltd. and Aditum Bio Management Company LLC have announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141.
Read more
Report
Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders
Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders
Read more
Report
Mabwell et Aditum Bio annoncent la création de Kalexo Bio pour faire avancer une thérapie innovante par siRNA contre les maladies cardiovasculaires
Read more
Report
迈威生物与 Aditum Bio 合作成立 Kalexo Bio共同推进心血管领域 siRNA 创新药的开发
来源：迈威生物转自：迈威生物重要新闻迈威生物688062.SH一家全产业链布局的创新型生物制药公司与 Aditum Bio Fund 3, L.P.以下简称
Read more
Report